{"meta":{"totalResults":7,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"cytarabine-daunorubicin-etoposide regimen"},{"type":"Synonym","name":"AraC-daunorubicin-etoposide regimen"},{"type":"Synonym","name":"cytarabine/daunorubicin/etoposide"},{"type":"Synonym","name":"ADE"},{"type":"Abbreviation","name":"ARA-C/DNR/VP-16"},{"type":"Synonym","name":"MRC AML10 study-ADE regimen"},{"type":"Synonym","name":"high-dose cytarabine-daunorubicin-etoposide regimen"},{"type":"Synonym","name":"high-dose cytarabine/daunorubicin/etoposide"},{"type":"Synonym","name":"high-dose cytarabine/daunorubicin/etoposide regimen"}],"definition":{"html":"A regimen consisting of high-dose cytarabine (Ara-C), daunorubicin and etoposide, that is used for the treatment of pediatric and adult acute myeloid leukemia (AML).","text":"A regimen consisting of high-dose cytarabine (Ara-C), daunorubicin and etoposide, that is used for the treatment of pediatric and adult acute myeloid leukemia (AML)."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/ADE","text":"ADE"},"nciConceptId":"C9579","nciConceptName":"ADE Regimen","termId":656988,"name":"ADE regimen","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"ade-regimen"},{"aliases":[{"type":"Abbreviation","name":"AIE"},{"type":"Synonym","name":"AraC-idarubicin-etoposide regimen"},{"type":"Synonym","name":"cytarabine-idarubicin-etoposide regimen"},{"type":"Abbreviation","name":"ICE"},{"type":"Synonym","name":"MRC AML10 study-AIE regimen"}],"definition":{"html":"A regimen consisting of cytarabine (Ara-C), idarubicin and etoposide, used as an induction treatment for pediatric acute myeloid leukemia (AML). High-dose cytarabine/etoposide/idarubicin regimen may be used for the treatment of AML.","text":"A regimen consisting of cytarabine (Ara-C), idarubicin and etoposide, used as an induction treatment for pediatric acute myeloid leukemia (AML). High-dose cytarabine/etoposide/idarubicin regimen may be used for the treatment of AML."},"drugInfoSummaryLink":null,"nciConceptId":"C67484","nciConceptName":"AIE Regimen","termId":789750,"name":"AIE regimen","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"aie-regimen"},{"aliases":[{"type":"Synonym","name":"Ara-C asparagine conjugate"},{"type":"Synonym","name":"cytarabine asparagine conjugate"},{"type":"CodeName","name":"BST236"},{"type":"Synonym","name":"asparagine cytarabine conjugate"},{"type":"CASRegistryName","name":"2098942-53-9"},{"type":"CodeName","name":"BST 236"},{"type":"CodeName","name":"BST-236"},{"type":"Synonym","name":"asparagine Ara-C conjugate"},{"type":"Synonym","name":"astarabine"}],"definition":{"html":"A small molecule pro-drug consisting of cytarabine, an antimetabolite analog of cytidine with a modified arabinose sugar moiety, covalently bonded to asparagine, with potential antineoplastic activity. Upon intravenous administration, aspacytarabine targets cancer cells, which often lack asparagine synthetase and are dependent on an external source of amino acids due to their high metabolic rate. Once the prodrug is inside target cells, the cytarabine component is cleaved and competes with cytidine for incorporation into DNA. The arabinose sugar moiety of cytarabine sterically hinders the rotation of the molecule within DNA, resulting in cell cycle arrest, specifically during the S phase of replication. Cytarabine also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Because BST-236 specifically targets cancer cells, it may spare normal tissues from cytarabine-related toxicities.","text":"A small molecule pro-drug consisting of cytarabine, an antimetabolite analog of cytidine with a modified arabinose sugar moiety, covalently bonded to asparagine, with potential antineoplastic activity. Upon intravenous administration, aspacytarabine targets cancer cells, which often lack asparagine synthetase and are dependent on an external source of amino acids due to their high metabolic rate. Once the prodrug is inside target cells, the cytarabine component is cleaved and competes with cytidine for incorporation into DNA. The arabinose sugar moiety of cytarabine sterically hinders the rotation of the molecule within DNA, resulting in cell cycle arrest, specifically during the S phase of replication. Cytarabine also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Because BST-236 specifically targets cancer cells, it may spare normal tissues from cytarabine-related toxicities."},"drugInfoSummaryLink":null,"nciConceptId":"C153327","nciConceptName":"Aspacytarabine","termId":795601,"name":"aspacytarabine","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"aspacytarabine"},{"aliases":[{"type":"Abbreviation","name":"ARA-C"},{"type":"ObsoleteName","name":"Cytosar-U"},{"type":"Synonym","name":"arabinofuranosylcytosine"},{"type":"Synonym","name":"arabinosylcytosine"},{"type":"Synonym","name":"cytosine arabinoside"},{"type":"ChemicalStructureName","name":"1-beta-D-arabinofuranosylcytosine"},{"type":"ChemicalStructureName","name":"4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone"},{"type":"ForeignBrandName","name":"ARA-cell"},{"type":"ForeignBrandName","name":"Alexan"},{"type":"ForeignBrandName","name":"Arabine"},{"type":"Synonym","name":"aracytidine"},{"type":"ForeignBrandName","name":"Aracytin"},{"type":"ForeignBrandName","name":"Aracytine"},{"type":"Synonym","name":"beta-cytosine arabinoside"},{"type":"CodeName","name":"CHX-3311"},{"type":"Synonym","name":"cytarabine hydrochloride"},{"type":"Synonym","name":"cytarabinum"},{"type":"ForeignBrandName","name":"Cytarbel"},{"type":"ForeignBrandName","name":"Cytosar"},{"type":"Synonym","name":"cytosine arabinosine hydrochloride"},{"type":"ForeignBrandName","name":"Erpalfa"},{"type":"Synonym","name":"tarabine PFS"},{"type":"CodeName","name":"U-19920"},{"type":"CodeName","name":"U-29920A HCl"},{"type":"ForeignBrandName","name":"Udicil"},{"type":"CodeName","name":"WR-28453"},{"type":"Synonym","name":"cytosine-.beta.-arabinoside"},{"type":"ForeignBrandName","name":"Starasid"},{"type":"ChemicalStructureName","name":"1.beta.-D-arabinofuranosylcytosine"},{"type":"ChemicalStructureName","name":"2(1H)-pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-"},{"type":"ChemicalStructureName","name":"1-.beta.-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone"},{"type":"Synonym","name":".beta.-Cytosine arabinoside"},{"type":"CodeName","name":"U 19920"},{"type":"INDCode","name":"1714"},{"type":"NSCNumber","name":"287459"},{"type":"CASRegistryName","name":"147-94-4"},{"type":"Synonym","name":"1-beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone"},{"type":"Synonym","name":"2(1H)-pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-"},{"type":"Synonym","name":"cytosine-beta-arabinoside"}],"definition":{"html":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair.","text":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/cytarabine","text":"Cytarabine"},"nciConceptId":"C408","nciConceptName":"Cytarabine","termId":39015,"name":"cytarabine","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cytarabine"},{"aliases":[{"type":"CodeName","name":"DTC 101"},{"type":"ObsoleteName","name":"DepoCyt"},{"type":"Synonym","name":"cytarabine liposomal"},{"type":"Synonym","name":"Liposomal Ara-C"},{"type":"ForeignBrandName","name":"DepoCyte"},{"type":"Synonym","name":"DepoFoam encapsulated cytarabine"},{"type":"Synonym","name":"encapsulated cytarabine"}],"definition":{"html":"A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death.","text":"A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death."},"drugInfoSummaryLink":null,"nciConceptId":"C2388","nciConceptName":"Liposomal Cytarabine","termId":42260,"name":"cytarabine liposome","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"liposomal-cytarabine"},{"aliases":[{"type":"CodeName","name":"MB07133"},{"type":"Synonym","name":"cytarabine prodrug MB07133"},{"type":"ChemicalStructureName","name":"(2R,4S)-4-amino-1-[5-O-[2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl]-beta-d-arabinofuranosyl]-2(1H)-pyrimidinone"}],"definition":{"html":"A prodrug of the monophosphate (MP) form of the antimetabolite cytarabine (araCMP), an analogue of cytidine with a modified sugar moiety (arabinose instead of ribose), with potential antineoplastic activity. Upon administration of the cytarabine MP prodrug MB07133, the targeting moiety of this agent specifically delivers the cytarabine moiety to the liver. In turn, araCMP is selectively converted to araC triphosphate (araCTP) by a liver kinase, where it binds to and competes with cytidine for incorporation into DNA, thereby inhibiting DNA polymerase, and DNA synthesis. This leads to the inhibition of tumor cell proliferation and destruction of liver cancer cells. The liver is not able to convert araC into araCMP; araCMP is not converted into araCTP in tissues other than the liver. This enhances efficacy and minimizes systemic toxicity.\n","text":"A prodrug of the monophosphate (MP) form of the antimetabolite cytarabine (araCMP), an analogue of cytidine with a modified sugar moiety (arabinose instead of ribose), with potential antineoplastic activity. Upon administration of the cytarabine MP prodrug MB07133, the targeting moiety of this agent specifically delivers the cytarabine moiety to the liver. In turn, araCMP is selectively converted to araC triphosphate (araCTP) by a liver kinase, where it binds to and competes with cytidine for incorporation into DNA, thereby inhibiting DNA polymerase, and DNA synthesis. This leads to the inhibition of tumor cell proliferation and destruction of liver cancer cells. The liver is not able to convert araC into araCMP; araCMP is not converted into araCTP in tissues other than the liver. This enhances efficacy and minimizes systemic toxicity.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C128888","nciConceptName":"Cytarabine Monophosphate Prodrug MB07133","termId":352009,"name":"cytarabine monophosphate prodrug MB07133","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cytarabine-monophosphate-prodrug-mb07133"},{"aliases":[{"type":"CodeName","name":"CPX-351"},{"type":"Synonym","name":"liposomal cytarabine-daunorubicin"},{"type":"Synonym","name":"liposome-encapsulated combination of daunorubicin and cytarabine"},{"type":"USBrandName","name":"Vyxeos"},{"type":"Synonym","name":"cytarabine-daunorubicin liposome for injection"},{"type":"Synonym","name":"liposomal AraC-daunorubicin CPX-351"},{"type":"Synonym","name":"cytarabine and daunorubicin liposomal"}],"definition":{"html":"A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.","text":"A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochlorideandcytarabineliposome","text":"Daunorubicin Hydrochloride and Cytarabine Liposome"},"nciConceptId":"C67504","nciConceptName":"Liposome-encapsulated Daunorubicin-Cytarabine","termId":554979,"name":"liposome-encapsulated daunorubicin-cytarabine","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"liposome-encapsulated-daunorubicin-cytarabine"}],"links":null}